Skip to main content

Beam Therapeutics Inc.

BEAM
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001745999

In the last 90 days, Beam Therapeutics Inc. insiders filed 0 open-market purchases and 2 sales; 262 institutions reported holding it in 13F filings for Q3 2026, worth $2.74B in total; superinvestors ARK Invest and Duquesne Family Office hold it.

Key figures

Market capClose on Nov 18, 2026
$2.17B
Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $1.19M in total
2
13F holdersQ3 2026, −9 vs. previous quarter
262
13F valueReported value at the end of Q3 2026
$2.74B
Superinvestors holdingAt the end of Q3 2026
2

Price chart

From SEC filings, in USD.

Revenue, FY2025
$139.7M
+120.0% year over year
Net income, FY2025
-$80.0M
No comparable prior period
Free cash flow, FY2025
-$360.0M
No comparable prior period
Revenue, Q3 FY2026
$307.0K
−96.8% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $80.0M (57.2% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
26.1M
Shares sold short
Change
−160.7K
−0.6% vs. previous
Days to cover
13.69
At average daily volume

Superinvestors holding BEAM, Q3 2026

Go to the superinvestors tab

2 superinvestors report holding Beam Therapeutics Inc. on Form 13F. Percentages are the stock's share of each portfolio.

ARK Invest

Cathie Wood

1.7%

Beam Therapeutics Inc.'s share of the portfolio

Shares
11,805,372
Value
$288.6M

Duquesne Family Office

Stanley Druckenmiller

0.4%

Beam Therapeutics Inc.'s share of the portfolio

Shares
699,700
Value
$17.1M

Latest insider trades

See all insider trades

Open-market purchases and sales by Beam Therapeutics Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Oct 16, 2026 (view filing)8:09 PM ETOct 15-161 dayEvans John M.CEOSSale−50.0K$23.77−$1.19M−4.6%1.05M after2 lots10b5-1
Oct 2, 2026 (view filing)4:05 PM ETOct 11 dayCavanagh Bethany JSVP, Finance and TreasurerSSale−187$24.41−$4.56K−0.4%51.0K after10b5-1
Jul 29, 2026 (view filing)4:05 PM ETJul 272 daysSimon AmyChief Medical OfficerSSale−16.7K$25.74−$429.0K−16.3%85.7K after10b5-1
Jul 2, 2026 (view filing)4:05 PM ETJun 302 daysSimon AmyChief Medical OfficerSSale−373$34.73−$13.0K−0.4%102.4K after10b5-1
Jul 1, 2026 (view filing)4:05 PM ETJun 29-302 daysEvans John M.CEOSSale−50.0K$34.90−$1.75M−4.6%1.05M after4 lots10b5-1
Jun 29, 2026 (view filing)Jun 25-264 daysFMR LLC10% Owner, Other: See Remark 1SSale−284.9K$35.24−$10.0M−25.0%854.6K after2 lots
Apr 6, 2026 (view filing)Apr 15 daysLateEvans John M.CEOSSale−30.1K$24.58−$739.3K−2.8%1.05M after10b5-1
Apr 6, 2026 (view filing)Apr 15 daysLateSimon AmyChief Medical OfficerSSale−6.70K$24.58−$164.7K−6.1%102.7K after10b5-1
Apr 6, 2026 (view filing)Apr 15 daysLateCavanagh Bethany JSVP, Finance and TreasurerSSale−3.24K$24.58−$79.7K−6.0%51.2K after10b5-1
Apr 6, 2026 (view filing)Apr 15 daysLateBellon ChristineChief Legal OfficerSSale−5.96K$24.58−$146.4K−5.1%109.7K after10b5-1

Top 10 13F holders, Q3 2026

See all 262 holders

The largest institutional positions in Beam Therapeutics Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding BEAM in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
FMR LLC12,926,476$316.1M0.01%+317,474+2.5%Added
ARK Investment Management LLCSuperinvestorARK Invest11,805,372$288.6M1.66%+1,570,510+15.3%Added
Farallon Capital Management, L.L.C.10,276,396$251.3M1.31%+40,000+0.4%Added
BlackRock, Inc.9,119,097$223.0M0.00%+121,555+1.4%Added
State Street Corp5,920,492$144.8M0.00%+93,370+1.6%Added
Vanguard Portfolio Management LLC4,901,651$119.8M0.01%−19,608−0.4%Reduced
Vanguard Capital Management LLC4,608,292$112.7M0.00%+8,855+0.2%Added
ARCH Venture Management, LLC4,540,132$111.0M6.88%00.0%Unchanged
Kynam Capital Management, LP3,933,894$96.2M5.33%+1,093,102+38.5%Added
Sumitomo Mitsui Trust Holdings, Inc.3,349,244$81.9M0.05%−105,799−3.1%Reduced

Holders of 5% or more of BEAM

See all 7 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Beam Therapeutics Inc..

Largest holders of BEAM from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
FMR LLC13G/A12.60%12.8M shares−1.00 ppfrom 13.60%Feb 8, 202111 filingsFeb 5, 2026SEC
ARK Investment Management LLCSuperinvestorARK Invest13G/A11.43%11.8M shares+1.48 ppfrom 9.95%Jun 10, 20219 filingsNov 13, 2026SEC
Farallon Capital Management, L.L.C.13G/A9.99%10.3M shares–Aug 13, 20261 filingAug 13, 2026SEC
Farallon Capital Partners, L.P.13G/A9.99%10.1M shares0.00 ppfrom 9.99%Jul 14, 20228 filingsFeb 5, 2026SEC
BlackRock, Inc.13G/A7.50%7.50M shares–Oct 21, 20243 filingsApr 17, 2025SEC